Contents

18 September 2019
Vol 11, Issue 510

About The Cover

Cover image expansion

ONLINE COVER HIV Vaccine on Trial. Polyfunctional HIV-specific T cells, depicted in this heatmap, contribute to protective immunity generated by vaccination. Gray et al. designed the HVTN 097 HIV vaccine trial in South Africa to test the RV144 regimen used in Thailand, which is the only HIV vaccine that has shown some efficacy. Although the HIV strains circulating in South Africa differ from those used to make the vaccine, strong immune responses associated with protection were observed. The vaccine seemed more immunogenic in the South African participants, suggesting that the RV144 HIV vaccine regimen could be used to prevent infection in areas where HIV is endemic. [CREDIT: GRAY ET AL./SCIENCE TRANSLATIONAL MEDICINE]